Surgical Endoscopy

, Volume 23, Issue 12, pp 2662–2664 | Cite as

Beyond quality-of-life improvement: how robotic surgery for low anterior resection with total mesorectal excision also may improve oncologic outcomes

Letter

References

  1. 1.
    Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J (2008) Long-term outcome of laparoscopic surgery for colorectal cancer: a Cochrane systematic review of randomised controlled trials. Cancer Treat Rev 34:498–504CrossRefPubMedGoogle Scholar
  2. 2.
    Hellan M, Stein H, Pigazzi A (2009) Totally robotic low anterior resection with total mesorectal excision and splenic flexure mobilization. Surg Endosc 23:447–451CrossRefPubMedGoogle Scholar
  3. 3.
    Luca F, Cenciarelli S, Valvo M et al (2009) Full robotic left colon and rectal cancer resection: technique and early outcome. Ann Surg Oncol 16(5):1274–1278CrossRefPubMedGoogle Scholar
  4. 4.
    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406CrossRefPubMedGoogle Scholar
  5. 5.
    Roukos DH (2009) Genome-wide association studies: how predicable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMedGoogle Scholar
  6. 6.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16:772–773CrossRefPubMedGoogle Scholar
  7. 7.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian knot”? Ann Surg Oncol 16:774–775CrossRefPubMedGoogle Scholar
  8. 8.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358:1636CrossRefPubMedGoogle Scholar
  9. 9.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9:1–6CrossRefPubMedGoogle Scholar
  10. 10.
    Roukos DH (2009) Mea Culpa with cancer targeted therapy: new thinking and new agents design for novel causal networks-based personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMedGoogle Scholar
  11. 11.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27:1337–1338CrossRefPubMedGoogle Scholar
  12. 12.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8:587–597CrossRefPubMedGoogle Scholar
  13. 13.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361CrossRefPubMedGoogle Scholar
  14. 14.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197CrossRefPubMedGoogle Scholar
  15. 15.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141CrossRefPubMedGoogle Scholar
  16. 16.
    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–1556CrossRefPubMedGoogle Scholar
  17. 17.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798CrossRefPubMedGoogle Scholar
  18. 18.
    Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8:29–39CrossRefPubMedGoogle Scholar
  19. 19.
    Liakakos T, Roukos DH (2008) More controversy than ever: challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15:956–960CrossRefPubMedGoogle Scholar
  20. 20.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715CrossRefPubMedGoogle Scholar
  21. 21.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9:828–830CrossRefPubMedGoogle Scholar
  22. 22.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7:719–726CrossRefPubMedGoogle Scholar
  23. 23.
    Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33CrossRefPubMedGoogle Scholar
  24. 24.
    Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (2004) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3:115–125CrossRefGoogle Scholar
  25. 25.
    Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129Google Scholar
  26. 26.
    Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721Google Scholar
  27. 27.
    Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5:737–745CrossRefPubMedGoogle Scholar
  28. 28.
    Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695PubMedCrossRefGoogle Scholar
  29. 29.
    Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221CrossRefPubMedGoogle Scholar
  30. 30.
    Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMedGoogle Scholar
  31. 31.
    Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas-Couchell S (1990) A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach: an analysis of early results and long-term survival. J Cancer Res Clin Oncol 116:307–311CrossRefPubMedGoogle Scholar
  32. 32.
    Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107CrossRefPubMedGoogle Scholar
  33. 33.
    Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predict gastric cancer recurrence risk and outcome, and determine potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84:1602–1609CrossRefPubMedGoogle Scholar
  34. 34.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362CrossRefPubMedGoogle Scholar
  35. 35.
    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943PubMedGoogle Scholar
  36. 35.
    Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Klinik für Allgemein-,Viszeral- und Endokrine Chirurgie, Asklepios Klinik LangenAkademisches Lehrkrankenhaus der Johann Wolfgang Goethe-UniversitätFrankfurtGermany
  2. 2.Department of Surgery, School of MedicineUniversity of IoanninaIoanninaGreece

Personalised recommendations